Axogen

Quote

anonymous said:
Wow, lots of bitter people out there. What did that small company really do piss so many of you off. Must have been pretty bad if you are still talking about it or failed that hard. Makes me wonder how many of you left vs. being asked to leave? Guess it wasn't the right place or the right time, but hell, guess that's living in the past ain't it.

Give you some advice, if you are still at AXGN and not happy, try finding a way to fix it. If you truly think a company you are working for won't at least hear what you have to say, then what does that say about you.

If you just need CP as an anonymous place to vent and feel like your a big sh!t, then carry on.g

Most people looking at a company on CP actually want to know the REAL picture, not a bunch of BS and bitter insecurities...get with the program people.

I'm going in for my interview this week. Guess we will see how it goes. If it's as bad as you say, it'll be some entertaining people watching.
Click to expand...



The fact you refer to another as "g" tells us all we need to know about you. And, no you are not interviewing for any position in the medical device field. They don't hire ignorant dumb fu@ks "g".
 
























anonymous said:
Yea, Rene Selman was escorted out of J&J over this way back when. She was a POS.

JS was a B player in all of this. However, as her track record indicates, JS is JS's biggest fan.
Click to expand...

Didn't know JS during this Ethicon issue but, I do know she was not well thought off by the reps at AxoGen. I'm not sure they saw any value in her position and yes, she apparently likes herself a great deal. However, her track record is indicative of a rolling stone. Lots of 1-3 yr gigs.
 
























What happened to this $$ was it paid to the sales reps?

ALACHUA, Fla.--(BUSINESS WIRE)-- AxoGen, Inc. (AxoGen) (OTCBB: AXGN), and PDL BioPharma, Inc. (PDL) (NAS: PDLI) , announced today that they closed a structured financing transaction on October 5, 2012 in which PDL provided AxoGen with an aggregate of $20.8 million. AxoGen is a regenerative medicine company dedicated to advancing the science and commercialization of surgical solutions for peripheral nerve repair.
 








anonymous said:
What happened to this $$ was it paid to the sales reps?

ALACHUA, Fla.--(BUSINESS WIRE)-- AxoGen, Inc. (AxoGen) (OTCBB: AXGN), and PDL BioPharma, Inc. (PDL) (NAS: PDLI) , announced today that they closed a structured financing transaction on October 5, 2012 in which PDL provided AxoGen with an aggregate of $20.8 million. AxoGen is a regenerative medicine company dedicated to advancing the science and commercialization of surgical solutions for peripheral nerve repair.
Click to expand...

Doesn't take the Head Cashier at Walmart to understand where the $$ is going via their financial reports. It's not a well managed company and one thing is clear, the " execs" at the top are going to take all they can, while they can. Reps are the last thing these hacks give a sh about.
 








anonymous said:
What happened to this $$ was it paid to the sales reps?

ALACHUA, Fla.--(BUSINESS WIRE)-- AxoGen, Inc. (AxoGen) (OTCBB: AXGN), and PDL BioPharma, Inc. (PDL) (NAS: PDLI) , announced today that they closed a structured financing transaction on October 5, 2012 in which PDL provided AxoGen with an aggregate of $20.8 million. AxoGen is a regenerative medicine company dedicated to advancing the science and commercialization of surgical solutions for peripheral nerve repair.
Click to expand...

lmfao!! What planet you've been on?
 
























1.5 hours

When/If Stryker buys Axogen, what will be the conflict between their existing conduits/nerve tubes and the conduits/nerve tubes sold by Axogen?

What % of total Axogen Sales is conduit/nerve tubes vs nerve tissue?
 








I would guess the graft accounts for about 40% of total sales - just a guess

How does the use of the graft affect the profitability of the surgery? Is the surgery a success and the hospital goes out of business?
 








Yes, if a company currently sells conduits, they would have to add the Axogen Conduits, or sell off their conduits to bring on the Axogen conduits.

Not an easy/straight forward bolt on at the suggested price multiples.
 








anonymous said:
1.5 hours

When/If Stryker buys Axogen, what will be the conflict between their existing conduits/nerve tubes and the conduits/nerve tubes sold by Axogen?

What % of total Axogen Sales is conduit/nerve tubes vs nerve tissue?
Click to expand...

Stryker has no interest in Axg but, then again nor would any well run entity. Axg has never turned a profit and has been mismanaged since its inception. Their financials are concerning are best. Axg's connectors would be nothing more than a " me too" to a Stryker or Integra with the science of their material unproven in superior efficacy. Thus, that leaves their graft which is a stand alone product and would be of interest to a company like S&N or Integra. However, with that tech comes grerat expense including shipping, handling, implanting and all for a small niche market.

Connectors out sell the graft and is where the profit ( mark up ) is located necessary to keep the lights on.
 








With that being said, how does Axogen continue to raise additional investment $ ?

Since its' inception, how much money has been burned to date?

If sold today, would the sale price be be larger than the amount burned to date?
 








It's that time of year, put on your Axogenic smile and head on down to the Womens' Club for a holiday dinner of dried out chicken and meatloaf!! Meet all your new team member!!
Axogenic!!!
 








anonymous said:
It's that time of year, put on your Axogenic smile and head on down to the Womens' Club for a holiday dinner of dried out chicken and meatloaf!! Meet all your new team member!!
Axogenic!!!
Click to expand...


You getting more than I ever received at holiday time. In 2 years as a field rep, I never received as much as a stinking email. F*** em all.
 








Stem Cell Medicine Ltd. (SCM), Ramot at Tel Aviv University Ltd. (Ramot), and Yeda Research and Development Company Ltd. (YEDA), announced today that they have entered into a license and research funding agreement. Under the terms of the agreement, SCM will fund Stem Cell-Based Treatments for Neuronal Diseases research at Tel Aviv University led by Professor Dani Offen, in cooperation with Professor David Yaffe of the Weizmann Institute of Science. SCM will hold the exclusive worldwide license for the development and the commercialization of the resulting technology and therapeutic product pipeline. SCM will develop products based on the technology through production and registration.

The research focuses on allogeneic, genetically modified muscle progenitor cell technology, comprised of four neurotrophic factors (NTFs), all of which play a key role in nerve regeneration. This technology, now licensed to SCM, will serve as the basis of new therapies intended for the treatment of several neuronal diseases. These include, but are not limited to, Peripheral Nerve Injury (PNI).
 








anonymous said:
You getting more than I ever received at holiday time. In 2 years as a field rep, I never received as much as a stinking email. F*** em all.
Click to expand...


Yes, as an ex AgoGen'r I would say there was never much respect or love directed towards the field but, you get use to it and learn to move on. However, if you are in need of feeling wanted, connected or appreciated, this ain't the gig for ya. Reality is - it's a check while you search for something bigger and better, nothing more.
 








Top Bottom
Back
Quote